DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into an exclusive evaluation and option to license agreement with Nobel Biocare , the world leader in innovative restorative and esthetic dental solutions. Under terms of the Agreement, Nobel Biocare will have an exclusive period to evaluate, negotiate commercialization terms and license the Company’s Cerashield™ antimicrobial technology for certain oral and cranial maxillofacial applications for a period of up to eleven months. This is the third such agreement entered into by Ceragenix for a medical device application of its CeraShield™ antimicrobial technology.
